RESUMEN
Self-assembled highly uniform microspheres from star-shaped biocompatible polymers have been prepared as a local delivery system for co-loading different immunoagents together and ensuring their release in different stages, so as to realize effective cooperative immunotherapy and minimize systemic side effects.
Asunto(s)
Antineoplásicos/uso terapéutico , Portadores de Fármacos/química , Melanoma/tratamiento farmacológico , Melanoma/terapia , Microesferas , Animales , Anticuerpos/inmunología , Anticuerpos/uso terapéutico , Línea Celular Tumoral , Sinergismo Farmacológico , Inhibidores Enzimáticos/uso terapéutico , Femenino , Inmunoterapia , Indolamina-Pirrol 2,3,-Dioxigenasa/antagonistas & inhibidores , Ratones Endogámicos C57BL , Polietilenglicoles/química , Receptor de Muerte Celular Programada 1/inmunología , Triptófano/análogos & derivados , Triptófano/uso terapéuticoRESUMEN
A highly sensitive and selective miRNA detection approach based on a small circular probe and dual signal amplification has been reported. We successfully applied the assay for quantitative let-7a detection in cell lysates and the results agreed well with those of qRT-PCR.
Asunto(s)
Técnicas Biosensibles , Colorantes Fluorescentes/química , MicroARNs/análisis , ADN Catalítico/química , ADN Catalítico/metabolismo , MicroARNs/genética , Polímeros/química , Polímeros/metabolismoRESUMEN
Mesenchymal stem cells are immunoregulation cells. IL-22 plays an important role in the pathogenesis of immune thrombocytopenia. However, the effects of mesenchymal stem cells on IL-22 production in patients with immune thrombocytopenia remain unclear. Flow cytometry analyzed immunophenotypes of mesenchymal stem cells; differentiation of mesenchymal stem cells was observed by oil red O and Alizarin red S staining; cell proliferation suppression was measured with MTS; IL-22 levels of cell-free supernatants were determined by ELISA. Mesenchymal stem cells inhibited the proliferation of activated CD4(+)T cells; moreover, mesenchymal stem cells immunosuppressed IL-22 by soluble cellular factors but not PGE2. These results suggest that mesenchymal stem cells may be a therapeutic strategy for patients with immune thrombocytopenia.